Novartis Says 'No' on Alnylam IP Option as Alternate RNAi Approaches Gain Traction
September 30, 2010
Novartis Says 'No' on Alnylam IP Option as Alternate RNAi Approaches Gain Traction
The emergence of new RNAi chemistries and technologies in recent years, and big pharma's growing interest in building up its own capabilities, suggest that Alnylam's status as the go-to partner in the field may be waning.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Novartis Extends Alnylam RNAi Rx Partnership for Fifth Year
July 23, 2009 / Gene Silencing News - Alnylam to Cut a Third of Its Staff on Heels of Pipeline Reorganization
January 26, 2012 / Gene Silencing News - In 2011, miRNAs Move Beyond 'Scientific Curiosity' as Big Pharma Externalizes Oligo Drug Development
January 5, 2012 / Gene Silencing News